Modelli di dati selezionati

Devi effettuare il log in per selezionare i modelli di dati da scaricare per successive analisi

20 Risultati di ricerca.
rilevanza Valutazione Più recente Meno recente

ANBL0321: CT/MRI Response Assessment Form NCT00053326

- 03/07/15 - 1 modulo, 4 itemgroups, 18 elementi, 1 linguaggio
Itemgroups: Header, CT/MRI Response Assessment, New Lesion, CCRR MODULE
ANBL0321: CT/MRI Response Assessment Form NCT00053326 Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B968DB9B-1F21-22F4-E034-0003BA12F5E7

Clinical activity of recMAGE-A3 + AS15 in patients with metastatic cutaneous melanoma NCT00942162 - Best overall response assessment; New tumor biopsy/ sample (Report Final and Annex Report 2 Final)

- 30/10/20 - 1 modulo, 3 itemgroups, 29 elementi, 1 linguaggio
Itemgroups: Administrative, Best overall response assessment, New tumor biopsy/ sample
Study ID: 111476 Clinical Study ID: 111476 Study Title: An open, single-arm trial to assess the clinical activity of recMAGE-A3 + AS15 in patients with unresectable MAGE-A3-positive metastatic cutaneous melanoma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00942162 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Antigen-Specific Cancer Immunotherapeutic Study Indication: Melanoma

ADVL0212: Response Assessment NCT00053963

- 05/07/15 - 1 modulo, 5 itemgroups, 14 elementi, 1 linguaggio
Itemgroups: Header, Sites of Measurable Disease at the Time of Study Entry, Evaluation of lesions, Comments, CCRR MODULE
ADVL0212: Response Assessment NCT00053963 FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B1EAE217-B511-30BD-E034-0003BA12F5E7

ANBL0321 MIBG Response NCT00053326

- 20/09/21 - 1 modulo, 5 itemgroups, 6 elementi, 1 linguaggio
Itemgroups: Header, Period Number, Tumor Response, Comments, CCRR MODULE
ANBL0321 MIBG Response NCT00053326 Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B968BED1-43CF-22DE-E034-0003BA12F5E7

ANBL0321: Bone Marrow Response NCT00053326

- 16/06/15 - 1 modulo, 3 itemgroups, 13 elementi, 1 linguaggio
Itemgroups: Header, Bone Marrow Response, CCRR MODULE
ANBL0321: Bone Marrow Response NCT00053326 Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B9B4AFEC-3E03-1FF8-E034-0003BA12F5E7

HIV Cancer Sunitinib NCT00890747 AMC-061 - Response Evaluation Form (R61)

- 24/06/17 - 1 modulo, 7 itemgroups, 35 elementi, 1 linguaggio
Itemgroups: Header Module, Complete Response, Morphologic Complete Remission, Complete Response, Unconfirmed, Complete Response with Incomplete Bone Marrow Recovery, PR, Progressive Disease
AMC-061 Response Evaluation Form (R61) Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy https://clinicaltrials.gov/ct2/show/NCT00890747

Response - Phase II Breast Cancer - Summary Response/Progression Form for Solid Tumors - 2582834v1.0 - Phase II Breast Cancer - Summary Response/Progression Form for Solid Tumors

- 08/01/15 - 1 modulo, 4 itemgroups, 25 elementi, 1 linguaggio
Itemgroups: CRF Header, Form Administration, Response Assessment, Comments
Phase II Breast Cancer - Summary Response/Progression Form for Solid Tumors Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=25794336-1BEF-04E8-E044-0003BA3F9857

SIOP CNS GCT II Response evaluation DRKS00003907 - Response evaluation

- 19/09/14 - 1 modulo, 9 itemgroups, 33 elementi, 2 lingue
Itemgroups: Show identification of patient, Response, Response evaluation: Cranial imaging, Response evaluation: Tumour site pineal, Response evaluation: Tumour site supra-/intrasellar, Response evaluation: Other tumour site, Response evaluation: Tumour volume, Response evaluation: Cranial imaging, CSF cytology
SIOP CNS GCT II: Prospective Trial for the Diagnosis and Treatment of Children, Adolescents and Young Adults With Intracranial Germ Cell Tumors. Principal Investigator Gabriele Calaminus, MD. http://clinicaltrials.gov/show/NCT01424839

ECOG Nontarget Lesions Supplemental Form (E2100)

- 28/07/15 - 1 modulo, 4 itemgroups, 20 elementi, 1 linguaggio
Itemgroups: ECOG clinical trial administrative data, NONTARGET LESIONS, Comments, CCRR MODULE
ECOG Nontarget Lesions Supplemental Form (E2100) Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=AC328486-403E-246F-E034-0003BA12F5E7

NSABP Protocol B-40 - Tumor Response Form NCT00408408

- 05/07/15 - 1 modulo, 5 itemgroups, 25 elementi, 1 linguaggio
Itemgroups: Header, Form completed by, Section A: Evaluation of Target Lesions, Section B: Evaluation of NonTarget Lesions, Section C: Manifestations of Progressive Disease
NSABP Protocol B-40 - Tumor Response Form NCT00408408 A Randomized Phase III Trial of Neoadjuvant Therapy in Patients With Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel When Administered Before AC With or Without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR With Each of the Regimens Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=1B7DC2CF-E4EE-1B7D-E044-0003BA3F9857

CALGB_40302_FU_SOL_TUM_EVAL_FRM NCT00390455

- 08/06/15 - 1 modulo, 6 itemgroups, 34 elementi, 1 linguaggio
Itemgroups: Header, Patient demographics, REPORTING PERIOD, NON-TARGET LESION(S) FOLLOW-UP EVALUATION, NEW LESION(S) AT FOLLOW-UP EVALUATION, OVERALL RESPONSE
CALGB 40302 FOLLOW-UP SOLID TUMOR EVALUATION FORM NCT00390455 Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=F593450E-79E6-42E1-E034-0003BA3F9857

CALGB: 49808 RESPONSE/PROGRESSION FORM NCT00016276

- 03/06/15 - 1 modulo, 4 itemgroups, 26 elementi, 1 linguaggio
Itemgroups: CALGB clinical trial administrative data, Patient clinical trial data, Response Assessment (Clinical/Radiographic), Comments
CALGB: 49808 RESPONSE/PROGRESSION FORM NCT00016276 Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=9E35395C-867B-227A-E034-080020C9C0E0

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial